Extended survival in patients with relapsed myeloma confirmed in Phase III trial results of Velcade

Published: 2004-09-17 06:57:00

Updated: 2004-09-17 06:57:00

In the final survival endpoint analysis in the Phase III confirmatory APEX study comparing patients receiving Velcade (bortezomib) injection to those receiving high-dose dexamethasone, Velcade produced a statistically significant survival benefit, said an official at Janssen Korea. Recently, the company launched in Korea Velcade for the treatment of patient with multiple myeloma.

The study w...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.